Linksys Launches Hydra Pro 6, the Newest Addition to its Lineup of WiFi 6 Routers
Linksys, a global leader in home and business WiFi solutions, today announces the availability of its latest and more affordable WiFi 6 product, the Hydra Pro 6.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220104005357/en/
Linksys Hydra Pro 6 (Photo: Business Wire)
“Our mission at Linksys is to connect everyone securely, whether it’s someone working from home who needs reliable WiFi or a student intently taking notes during their online class. The Hydra Pro 6 is our latest router in a suite of products that offer next-level streaming, are easy to set up and equipped with advanced security and parental controls,” said Harry Dewhirst, CEO, Linksys. “People shouldn’t worry about a dropped video chat or connections that aren’t secure. WiFi is meant to make life easier not create unnecessary problems in an already difficult world. We are committed to delivering fast, reliable, and secure connectivity to the hybrid work era and beyond, and the Hydra Pro 6 is just the start.”
The Linksys Hydra Pro 6 delivers the ultimate WiFi 6 experience to 30+ devices (per node) across 2700 sq. ft. of coverage and wireless speeds up to 5.4 Gbps. Powered by the Qualcomm® Immersive Home 216 Platform plus access to 160 MHz channel, the Hydra Pro 6 unleashes the true power of WiFi 6 with reliable, incredibly fast connectivity and improved network efficiency for seamless video streaming, faster downloading and more. Intelligent Mesh technology offers whole home mesh WiFi coverage that’s easily expandable by adding nodes.
At a time when device-heavy homes are more dependent on WiFi than ever before, the powerful yet easy to use Hydra Pro 6 is a seamless addition to households and allows users to view/prioritize devices through the free Linksys app. Additional features include WPA3/WPA2-Personal encryption and SPI firewall, automatic security updates, parental controls, and a separate guest network.
The Linksys Hydra Pro 6 is available now in the U.S. for $299 on Linksys.com and is coming soon to major retailers across the globe. For more information on the product please visit: https://www.linksys.com/us/p/p-mr5500/
Product imagery can be found here.
About Linksys
At Linksys, we strive to build the world’s most reliable, innovative, future-ready wireless technologies that can securely connect every person and everything, effortlessly. Founded in 1988, Linksys has since established itself as a premier networking brand. Today, Linksys hardware products, software, and services are sold in 64 countries worldwide, ranging from home routers and mesh systems to business access points and switches. Recently, Linksys expanded into education and enterprise through its partnership with Fortinet, the leader in enterprise-grade security. Linksys. For every connection.
Qualcomm is a trademark or registered trademark of Qualcomm Incorporated.
Qualcomm Immersive Home Platform is a product of Qualcomm Technologies, Inc. and/or its subsidiaries.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220104005357/en/
Contact information
Asees Singh
Sr. Global Communications Manager
Comms@linksys.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 13:31:00 EET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 01:49:00 EET | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive Officer, Lattice Semiconductor. The annual GSA Awards celebrate the accomplishments of the semiconductor indu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom